Capital Performance Advisors LLP Biotechnology

Capital Performance Advisors LLP

$325 Million
Q3 2024

Stock List

Stock	Market Cap.	Holding Value (Reported)	# of Shares.	Last Trade	Trade History
KYMR Kymera Therapeutics, Inc.	$2.54B	$0 0.0% of portfolio	3	Q3 2024 New
PRLD Prelude Therapeutics Inc	$45.1M	$0 0.0% of portfolio	8	Q3 2024 New
CCCC C4 Therapeutics, Inc.	$274M	$0 0.0% of portfolio	54	Q3 2024 New
TARS Tarsus Pharmaceuticals, Inc.	$1.26B	$0 0.0% of portfolio	5	Q3 2024 New
FHTX Foghorn Therapeutics Inc.	$346M	$0 0.0% of portfolio	14	Q3 2024 New
AVIR Atea Pharmaceuticals, Inc.	$274M	$0 0.0% of portfolio	31	Q3 2024 New
GLSI Greenwich Life Sciences, Inc.	$173M	$0 0.0% of portfolio	1	Q3 2024 New
SBTX Silverback Therapeutics, Inc.	$0	$0 0.0% of portfolio	33	Q3 2024 New
NUVB Nuvation Bio Inc.	$500M	$0 0.0% of portfolio	281	Q3 2024 New
CGEM Cullinan Oncology, Inc.	$720M	$0 0.0% of portfolio	13	Q3 2024 New
HUMA Humacyte, Inc.	$555M	$0 0.0% of portfolio	130	Q3 2024 New
SANA Sana Biotechnology, Inc.	$696M	$0 0.0% of portfolio	60	Q3 2024 New
TERN Terns Pharmaceuticals, Inc.	$258M	$0 0.0% of portfolio	23	Q3 2024 New
DSGN Design Therapeutics, Inc.	$290M	$0 0.0% of portfolio	143	Q3 2024 New
EWTX Edgewise Therapeutics, Inc.	$2.15B	$0 0.0% of portfolio	20	Q3 2024 New
BMEA Biomea Fusion, Inc.	$265M	$0 0.0% of portfolio	2	Q3 2024 New
HOWL Werewolf Therapeutics, Inc.	$73.2M	$0 0.0% of portfolio	60	Q3 2024 New
VERA Vera Therapeutics, Inc.	$1.18B	$0 0.0% of portfolio	11	Q3 2024 New
JANX Janux Therapeutics, Inc.	$2.27B	$0 0.0% of portfolio	17	Q3 2024 New
LYEL Lyell Immunopharma, Inc.	$278M	$0 0.0% of portfolio	171	Q3 2024 New
IPSC Century Therapeutics, Inc.	$74.2M	$0 0.0% of portfolio	12	Q3 2024 New
VERV Verve Therapeutics, Inc.	$355M	$0 0.0% of portfolio	141	Q3 2024 New
GLUE Monte Rosa Therapeutics, Inc.	$416M	$0 0.0% of portfolio	29	Q3 2024 New
AVTE Aerovate Therapeutics, Inc.	$68.2M	$0 0.0% of portfolio	80	Q3 2024 New
ABOS Acumen Pharmaceuticals, Inc.	$115M	$0 0.0% of portfolio	52	Q3 2024 New
ELEV Elevation Oncology, Inc.	$13.3M	$0 0.0% of portfolio	11	Q3 2024 New
ERAS Erasca, Inc.	$332M	$0 0.0% of portfolio	332	Q3 2024 New
TNYA Tenaya Therapeutics, Inc.	$80.2M	$0 0.0% of portfolio	12	Q3 2024 New
CMPX Compass Therapeutics, Inc.	$172M	$0 0.0% of portfolio	172	Q3 2024 New
TYRA Tyra Biosciences, Inc.	$688M	$0 0.0% of portfolio	5	Q3 2024 New
VTYX Ventyx Biosciences, Inc.	$122M	$0 0.0% of portfolio	173	Q3 2024 New
AURA Aura Biosciences, Inc.	$297M	$0 0.0% of portfolio	25	Q3 2024 New
TSVT 2seventy Bio, Inc.	$167M	$0 0.0% of portfolio	24	Q3 2024 New
PEPG Pep Gen Inc.	$164M	$0 0.0% of portfolio	13	Q3 2024 New
PROK Prokidney Corp Ord Shs Cl A(Cy	$95.4M	$0 0.0% of portfolio	279	Q3 2024 New
THRD Third Harmonic Bio, Inc.	$578M	$0 0.0% of portfolio	25	Q3 2024 New

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Capital Performance Advisors LLP, based on Form 13F filings with the SEC.

News

Stay updated on Capital Performance Advisors LLP with notifications on news.